Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felipe Batalini

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.
JCO Precision Oncology|April 3, 2026
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal CancerDaniel Walden, Felipe Batalini, Cody Eslinger, et al.
Breast Cancer Research and Treatment|April 16, 2026
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysisLorrany Larisse Costa Rodrigues, Lara de Holanda Jucá Silveira, Luiz Felipe C de Almeida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian CancersFelipe Batalini, Doga C Gulhan, Victor Mao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2025
Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence RoundBhavika K Patel, Molly B Carnahan, Donald Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence RoundBhavika K Patel, Molly B Carnahan, Donald Northfelt, et al.
Cancer Communications (London, England)|October 10, 2024
Genomic imprinting biomarkers for cervical cancer risk stratificationXue Xiao, Wei Wang, Peng Bai, et al.
Clinical Breast Cancer|November 8, 2024
Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic ExperienceNusrat Jahan, Jodi Taraba, Nicholas J Boddicker, et al.
Cell Reports|October 12, 2022
PARP-inhibition reprograms macrophages toward an anti-tumor phenotypeLin Wang, Dan Wang, Olmo Sonzogni, et al.
Research Square|January 30, 2023
Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerabilityShizhong Ke, Fabin Dang, Lin Wang, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.
JCO Precision Oncology|April 3, 2026
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal CancerDaniel Walden, Felipe Batalini, Cody Eslinger, et al.
Breast Cancer Research and Treatment|April 16, 2026
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysisLorrany Larisse Costa Rodrigues, Lara de Holanda Jucá Silveira, Luiz Felipe C de Almeida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian CancersFelipe Batalini, Doga C Gulhan, Victor Mao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2025
Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence RoundBhavika K Patel, Molly B Carnahan, Donald Northfelt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence RoundBhavika K Patel, Molly B Carnahan, Donald Northfelt, et al.
Cancer Communications (London, England)|October 10, 2024
Genomic imprinting biomarkers for cervical cancer risk stratificationXue Xiao, Wei Wang, Peng Bai, et al.
Clinical Breast Cancer|November 8, 2024
Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic ExperienceNusrat Jahan, Jodi Taraba, Nicholas J Boddicker, et al.
Cell Reports|October 12, 2022
PARP-inhibition reprograms macrophages toward an anti-tumor phenotypeLin Wang, Dan Wang, Olmo Sonzogni, et al.
Research Square|January 30, 2023
Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerabilityShizhong Ke, Fabin Dang, Lin Wang, et al.
Pageof 6